Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 888 | 922 | 888 | 517 | 948 | - |
Fund Return | -11.23% | -7.79% | -11.23% | -19.75% | -1.06% | - |
Place in category | 43 | 64 | 43 | 133 | 32 | - |
% in Category | 16 | 22 | 16 | 82 | 50 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
GF Stable Growth Mixed Assets Fund | 13.8B | 0.10 | -4.40 | 9.02 | ||
GF NASDAQ 100 Index Fund QDIII | 12.49B | 24.57 | 11.28 | 18.27 | ||
GF Tech Pioneer Alloc | 9.98B | 6.85 | -18.33 | - | ||
GF Global Selction Eq QDII | 8.35B | 26.78 | 9.01 | 13.11 | ||
GF Small-Cap Growth Stock Fd(LOF) | 6.67B | -4.82 | -18.37 | 6.46 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
ICBCCS QY Medical Eq | 12.06B | -14.85 | -14.87 | - | ||
CMF CNI Bio Health Index | 11.05B | -22.88 | -23.44 | - | ||
Hwabao WP CSI Medical Index | 6.98B | -15.28 | -20.32 | - | ||
China Universal Healthcare Serv mix | 3.44B | -8.02 | -17.29 | - | ||
Penghua Medical Tech Eq | 3.31B | -14.47 | -6.38 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Sichuan Biokin Pharmaceutical | CNE100006FN4 | 8.22 | 193.94 | -0.84% | |
Sinopep Allsino Bio Pharmaceutical Co | CNE1000051X5 | 4.74 | 50.18 | -0.38% | |
Kelun Pharm A | CNE100000PW7 | 4.58 | 28.28 | -1.33% | |
Jiangsu Hengrui | CNE0000014W7 | 4.08 | 44.66 | +0.31% | |
Suzhou Zelgen Biopharma | CNE100003RP1 | 3.51 | 64.85 | -1.58% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Sell | Strong Sell |
Technical Indicators | Strong Buy | Strong Sell | Strong Sell |
Summary | Neutral | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review